Federsel, Hans-Jürgen.
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Hans-jürgen Federsel
Federsel, Hans-Jürgen, 1949-
VIAF ID: 94503639 (Personal)
Permalink: http://viaf.org/viaf/94503639
Preferred Forms
-
100 1 _
‡a
Federsel, Hans-Jurgen
-
100 1 _ ‡a Federsel, Hans-Jurgen
-
100 1 _ ‡a Federsel, Hans-Jurgen
-
100 1 _
‡a
Federsel, Hans-Jürgen
-
100 1 _
‡a
Federsel, Hans-Jürgen
(sparse)
-
100 1 _
‡a
Federsel, Hans-Jürgen
-
100 1 _ ‡a Federsel, Hans-Jürgen
-
100 1 _ ‡a Federsel, Hans-Jürgen, ‡d 1949-
-
100 1 _ ‡a Federsel, Hans-Jürgen.
-
100 0 _
‡a
Hans-jürgen Federsel
4xx's: Alternate Name Forms (3)
Works
| Title | Sources |
|---|---|
| Asymmetric catalysis on industrial scale : challenges, approaches, and solutions |
|
| Asymmetry on large scale: the roadmap to stereoselective processes |
|
| Base-induced rearrangements of haloalkyl substituted quaternized thiazoles and related systems |
|
| Chlorodifluoromethyl phenyl sulfone: a novel non-ozone-depleting substance-based difluorocarbene reagent for O- and N-difluoromethylations. |
|
| Construction of a chiral central nervous system (CNS)-active aminotetralin drug compound based on a synthesis strategy using multitasking properties of (S)-1-phenylethylamine |
|
| Crystal structures of the Chromobacterium violaceumω-transaminase reveal major structural rearrangements upon binding of coenzyme PLP |
|
| Facing chirality in the 21st century: Approaching the challenges in the pharmaceutical industry |
|
| Factors influencing the selectivity in asymmetric oxidation of sulfides attached to nitrogen containing heterocycles |
|
| Handing over the baton: connecting medicinal chemistry with process R&D |
|
| How to conduct research in the pharmaceutical industry? Facing the dilemma: small, autonomous teams versus large, integrated centers. |
|
| In search of sustainability: process R&D in light of current pharmaceutical industry challenges |
|
| The integration of process R&D in drug discovery--challenges and opportunities |
|
| Process R&D under the magnifying glass: organization, business model, challenges, and scientific context |
|
| Regioisomerism in the synthesis of a chiral aminotetralin drug compound: unraveling mechanistic details and diastereomer-specific in-depth NMR investigations |
|
| Start small, think big--the art of process R&D |
|
| An unbalanced portfolio. |
|
